Brain and central nervous system cancer: clinical quality performance indicators - engagement document

11. References

1. Scottish Government (2016). . Beating Cancer: Ambition and Action

2. NICE (2006) Improving outcomes for people with brain and other CNS tumours – the manual (accessed on: 23rd August 2013)

3. NHS Quality Improvement Scotland (2008) Clinical standards for the management of bowel cancer (accessed 3rd June 2013).

4. Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas (2022).

Guideline from the College of American Pathologists in collaboration with the American Association of Neuropathologists, Association of Molecular Pathology, and Society for Neuro-Oncology.

5. B.W. Kristensen, L.P. Priesterbach-Ackley, J.K. Petersen, P. Wesseling. (2019) Molecular pathology of tumors of the central nervous system, Annals of Oncology, Volume 30, Issue 8. Pages 1265-1278.

6. Alberta Health Services (2008) Anaplastic astrocytomas and oligodendrogliomas (accessed 23rd August 2013).

7. Louis DN, Perry A, Reifenberger G, von Deimling A et al (2016) World Health Organization Histological Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer, France (accessed November 2017).

8. Stummer W, Pichlmeier U, Meinel T, et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7(5):392-401.

9. Pichlmeier U, Bink A, Schackert G, et al (2008) Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients. Neuro-oncology 2008; 10; 1024-1035.

10. Ryken TC, Frankel B, Julien T, Olson JJ (2008) Surgical management of newly diagnosed glioblastoma in adults: Role of cytoreductive surgery. Journal of Neuro-Oncology. 2008;(3):271-286.

11. NICE QS 203 – Brain Tumours (Primary) and Brain Metastases in over 16’s.

12. NICE NG99 - Brain Tumours (Primary) and Brain Metastases in over 16’s

13. Martin J. van den Bent, et al (2009) End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald’s Criteria. Journal of Clinical Oncology. 2009; 27(18): 2905-8.

14. Ulmer S, Braga TA, Barker FG 2nd, et al (2006) Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology. 2006; 67:1668-1670.

15. Cairncross JG, Pexman JH, Rathbone MP, et al (1985) Postoperative contrast enhancement in patients with brain tumor. Annals of Neurology. 1985; 17: 570-572.

16. Sato N, Bronen RA, Sze G, et al (1997) Postoperative changes in the brain: MR imaging findings in patients without neoplasms. Radiology. 1997; 204:839-846.

17. Smith JS, Cha S, Mayo MC, et al (2005) Serial diffusion-weighted magnetic resonance imaging in cases of glioma: Distinguishing tumor recurrence from postresection injury. Journal of Neurosurgery. 2005; 103: 428-438.

18. Irwin C, Hunn M, Purdie G, Hamilton D (2007) Delay in radiotherapy shortens survival in patients with high grade glioma. Journal of Neurooncology. 2007; 85 (3): 339-43.

19. Valduvieco I, Verger E, Bruna J, Caral L et al (2013) Impact of radiotherapy delay on survival in glioblastoma. Clinical & Translational Oncology. 2013; 5(4):278-82

20. NICE (2013) Epilepsy in Adults: Quality Standard 26.

21. NICE (2005) Referral guidelines for suspected cancer (accessed 23rd August 2013).

22. SIGN (2003) Diagnosis and Management of Epilepsy in Adults (accessed 23rd August 2013).

23. De Swart ME, Müller DMJ, Ardon H, et al. (2022) Between-hospital variation in time to glioblastoma surgery: a report from the Quality Registry Neuro Surgery in the Netherlands. J Neurosurg. 2022 Mar 11:1-10. doi: 10.3171/2022.1.JNS212566. Epub ahead of print. PMID: 35276655.

24. Müller DMJ, De Swart ME, Ardon H, et al. (2021) Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study. Neurooncol Adv. 2021 Apr 8;3(1):vdab053. doi: 10.1093/noajnl/vdab053. PMID: 34056605; PMCID: PMC8156977.

25. Parsons MW, Dietrich J. Assessment and Management of Cognitive Symptoms in Patients with Brain Tumors. Am Soc Clin Oncol Educ Book. 2021 Jun;41:e90-e99.

26. Zangrossi, A., Silvestri, E., Bisio, M., Bertoldo, A., De Pellegrin, S., Vallesi, A., Della Puppa, A. D'Avella, D., Denaro, L., Scienza, R. and Mondini, S., 2022. Presurgical predictors of early cognitive outcome after brain tumor resection in glioma patients. NeuroImage: Clinical, 36, p.103219.

27. Sierpowska, J, Rofes A, Dahlslätt K, Mandonnet E et al (2022). The Aftercare Survey: Assessment and intervention practices after brain tumor surgery in Europe, Neuro-Oncology Practice, Volume 9, Issue 4, August 2022, Pages 328–337

28. Brouwers M, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna S, Littlejohns P, Makarski J, Zitzelsberger L for the AGREE Next Steps Consortium (2010). AGREE II: Advancing guideline development, reporting and evaluation in healthcare. Can Med Assoc J. 182(18), E839-E842.